Effect of Varying Degrees of Hepatic Impairment on the Pharmacokinetics of Omecamtiv Mecarbil.
Sign Up to like & getrecommendations! Published in 2021 at "Clinical pharmacology in drug development"
DOI: 10.1002/cpdd.969
Abstract: Omecamtiv mecarbil (OM) is a novel selective cardiac myosin activator under investigation for the treatment of heart failure with reduced ejection fraction. OM is primarily eliminated via metabolism mediated by multiple cytochrome P450 enzymes. This… read more here.
Keywords: omecamtiv mecarbil; hepatic impairment; moderate hepatic; impairment ... See more keywords
Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment
Sign Up to like & getrecommendations! Published in 2019 at "Advances in Therapy"
DOI: 10.1007/s12325-019-01121-2
Abstract: Introduction The mineralocorticoid receptor (MR) blocker esaxerenone is a new treatment for hypertension in Japan and under development for treatment of diabetic nephropathy. Hepatic impairment is known to impact the pharmacokinetics (PKs) of other MR… read more here.
Keywords: normal hepatic; hepatic impairment; moderate hepatic; impairment ... See more keywords